The knockdown of METTL3, an m6A methyltransferase, suppressed pancreatic cancer malignancy and gemcitabine resistance by regulating its direct target DDX23 mRNA, thus PI3K/Akt signaling. The gene discussed is METTL3; the disease is pancreatic neoplasm.